QNCX
QNCX
NASDAQ · Biotechnology

Quince Therapeutics Inc

$0.10
+0.01 (+13.70%)
Financial Highlights (FY 2025)
Revenue
548.9K
Net Income
128.1K
Gross Margin
29.9%
Profit Margin
23.3%
Rev Growth
+23.9%
D/E Ratio
0.65
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 29.9% 29.9% 29.9%
Operating Margin 27.1% 23.2% 26.7%
Profit Margin 23.3% 20.7% 24.3%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 548.9K 523.5K 509.5K
Gross Profit 164.0K 156.4K 152.2K
Operating Income 148.5K 121.4K 136.2K
Net Income 128.1K 108.5K 123.6K
Gross Margin 29.9% 29.9% 29.9%
Operating Margin 27.1% 23.2% 26.7%
Profit Margin 23.3% 20.7% 24.3%
Rev Growth +23.9% +19.4% -4.0%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 2.85M 2.90M 3.28M
Total Equity 4.40M 4.55M 4.34M
D/E Ratio 0.65 0.64 0.76
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 177.1K 173.7K 174.5K
Free Cash Flow 145.7K 139.2K 108.0K